biostudies-literatureUnknown27(4)Pallett SJWellcome TrustEngineering and Physical Sciences Research CouncilIntroductionImmunoassays targeting different SARS-CoV-2-specific antibodies are employed for seroprevalence studies. The degree of variability between immunoassays targeting anti-nucleocapsid (anti-NP; the majority) vs the potentially neutralising anti-spike antibodies (including anti-receptor-binding domain; anti-RBD), particularly in mild or asymptomatic disease, remains unclear.AimsWe aimed to explore variability in anti-NP and anti-RBD antibody detectability following mild symptomatic or asymptomatic SARS-CoV-2 infection and analyse antibody response for correlation with symptomatology.MethodsA multicentre prospective cross-sectional study was undertaken (April-July 2020). Paired serum samples were tested for anti-NP and anti-RBD IgG antibodies and reactivity expressed as binding ratioEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC8796290biostudies-literatureVariability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020.PMC8796290EP/N002474/1209411/Z/17/ZEP/M027007/1Denny SJPantelidis PMcClure MOPatel ARandell PAbdulaal ARayment MMoore LSO'Shea MKPallett SJPallett MAToumazou CRosadas de Oliveira CKhan MJones RTedder RDavies GWMughal NfalseVariability in detection of SARS-CoV-2-specific antibody responses following mild infection: a prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020.IntroductionImmunoassays targeting different SARS-CoV-2-specific antibodies are employed for seroprevalence studies. The degree of variability between immunoassays targeting anti-nucleocapsid (anti-NP; the majority) vs the potentially neutralising anti-spike antibodies (including anti-receptor-binding domain; anti-RBD), particularly in mild or asymptomatic disease, remains unclear.AimsWe aimed to explore variability in anti-NP and anti-RBD antibody detectability following mild symptomatic or asymptomatic SARS-CoV-2 infection and analyse antibody response for correlation with symptomatology.MethodsA multicentre prospective cross-sectional study was undertaken (April-July 2020). Paired serum samples were tested for anti-NP and anti-RBD IgG antibodies and reactivity expressed as binding ratio2022-01-01T00:00:00Z2022 Jan2025-04-04T08:41:29.796Z2025-04-04T08:41:29.796ZS-EPMC87962903508661210.2807/1560-7917.ES.2022.27.4.2002076